Although the two primary ways to prevent and control influenza today are annual immunization and antiviral drugs, a team of investigators has found that statins may offer an additional treatment to complement these approaches and reduce mortality among patients hospitalized with influenza.
In an observational study led by Meredith L. Vandermeer, MPH, then with the Oregon Public Health Division in Portland, researchers used data for hospitalized adults during the 2007-2008 influenza season to evaluate the association between patients prescribed statins and influenza-related deaths.
The data were drawn from the Centers for Disease Control and Prevention's Emerging Infections Program, which conducts active surveillance for patients hospitalized with confirmed influenza in 59 counties in 10 states.
Among 3,043 hospitalized patients with laboratory-confirmed influenza, 33% were given statin medications prior to or during hospitalization. After adjusting for various factors, patients not receiving statins were almost twice as likely to die from influenza as those who did receive the medication.
"Our study found that statins were associated with a decrease in odds of dying among cases hospitalized with laboratory-confirmed influenza, when adjusted for age, race, cardiovascular disease, chronic lung disease, renal disease, influenza vaccine receipt and initiation of antivirals within 48 hours of admission," the authors wrote.
Because the study was observational, the authors noted there may have been confounding factors that were not found through reviews of patients' charts. Researchers also did not attempt to track the amount of statin use by patients during their hospital stay.
Randomized controlled trials would best address the potential benefits of statins for influenza treatment, the researchers concluded, and "would allow for examination of such issues as dose response, use in younger age groups and identifying the most effective class of statins."
In an accompanying editorial, Edward E. Walsh, MD, of the Infectious Diseases Division at Rochester General Hospital in Rochester, N.Y., noted that there have been previous observational studies suggesting statins may reduce mortality from influenza and pneumonia.
"One of the most important strengths of the current study," he wrote, "is that only patients with laboratory-confirmed influenza were included in the analysis," thus avoiding the uncertainty of potential disease misclassification in other methods.
The findings appeared Wednesday on the website of The Journal of Infectious Diseases. To read a summary and access the study via subscription or purchase, visit http://bit.ly/tJGMoG.
In an observational study led by Meredith L. Vandermeer, MPH, then with the Oregon Public Health Division in Portland, researchers used data for hospitalized adults during the 2007-2008 influenza season to evaluate the association between patients prescribed statins and influenza-related deaths.
The data were drawn from the Centers for Disease Control and Prevention's Emerging Infections Program, which conducts active surveillance for patients hospitalized with confirmed influenza in 59 counties in 10 states.
Among 3,043 hospitalized patients with laboratory-confirmed influenza, 33% were given statin medications prior to or during hospitalization. After adjusting for various factors, patients not receiving statins were almost twice as likely to die from influenza as those who did receive the medication.
"Our study found that statins were associated with a decrease in odds of dying among cases hospitalized with laboratory-confirmed influenza, when adjusted for age, race, cardiovascular disease, chronic lung disease, renal disease, influenza vaccine receipt and initiation of antivirals within 48 hours of admission," the authors wrote.
Because the study was observational, the authors noted there may have been confounding factors that were not found through reviews of patients' charts. Researchers also did not attempt to track the amount of statin use by patients during their hospital stay.
Randomized controlled trials would best address the potential benefits of statins for influenza treatment, the researchers concluded, and "would allow for examination of such issues as dose response, use in younger age groups and identifying the most effective class of statins."
In an accompanying editorial, Edward E. Walsh, MD, of the Infectious Diseases Division at Rochester General Hospital in Rochester, N.Y., noted that there have been previous observational studies suggesting statins may reduce mortality from influenza and pneumonia.
"One of the most important strengths of the current study," he wrote, "is that only patients with laboratory-confirmed influenza were included in the analysis," thus avoiding the uncertainty of potential disease misclassification in other methods.
The findings appeared Wednesday on the website of The Journal of Infectious Diseases. To read a summary and access the study via subscription or purchase, visit http://bit.ly/tJGMoG.
Send comments to editor@nurse.com or post comments below.
